How have KTTA shares performed in 2024?

Pasithea Therapeutics' stock was trading at $7.40 at the start of the year. Since then, KTTA stock has decreased by 3.4% and is now trading at $7.15. View the best growth stocks for 2024 here .

When is Pasithea Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, June 27th 2024. View our KTTA earnings forecast .

When did Pasithea Therapeutics' stock split?

Pasithea Therapeutics shares reverse split on Tuesday, January 2nd 2024. The 1-20 reverse split was announced on Tuesday, January 2nd 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

When did Pasithea Therapeutics IPO?

Pasithea Therapeutics (KTTA) raised $17 million in an IPO on Wednesday, September 15th 2021. The company issued 2,898,551 shares at $5.00-$7.00 per share.

How do I buy shares of Pasithea Therapeutics?

Shares of KTTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:KTTA

Pasithea Therapeutics (KTTA) Stock Price, News & Analysis

→ Forget Nvidia, buy this A.I. Stock Now (From InvestorPlace) (Ad)

Free KTTA Stock Alerts

$7.15

-0.10 (-1.38%)

(As of 04/17/2024 ET)

Compare

Today's Range: $7.15
▼
$7.15
50-Day Range: $5.80
▼
$8.75
52-Week Range: $5.25
▼
$17.40

Volume: 349 shs
Average Volume: 10,098 shs
Market Capitalization: $7.44 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Pasithea Therapeutics alerts:

Ad InvestorPlace

Forget Nvidia, buy this A.I. Stock Now

Forget Nvidia, Microsoft or Google. Our tech expert and venture capitalist Luke Lango believes this is Elon Musk’s favorite A.I. stock. Why? Because this company is supplying Elon Musk with a key piece of advanced tech for his new A.I. venture.

Click here to see the details.

About Pasithea Therapeutics Stock (NASDAQ:KTTA)

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for Central Nervous System disorders, RASopathies, and other diseases. It operates through two segments, Therapeutics and Clinics. The company provides business support services to anti-depression clinics, entities, and registered healthcare providers. Its lead product candidate PAS-004, a next-generation mitogen-activated protein kinase, or MEK inhibitor designed to be macrocyclic for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 and Noonan syndrome, as well as lamin A/C cardiomyopathy and oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; PAS-002, for the treatment multiple sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

KTTA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

KTTA Stock News Headlines

February 13, 2024 | finance.yahoo.com

Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004

January 8, 2024 | finance.yahoo.com

Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position

April 17, 2024 | InvestorPlace (Ad)

Forget Nvidia, buy this A.I. Stock Now

January 2, 2024 | msn.com

Pasithea Jumps as FDA Grants IND Status to Cancer Treatment

January 2, 2024 | markets.businessinsider.com

Pasithea Therapeutics' IND Application For PAS-004 Gets FDA Acceptance

January 2, 2024 | seekingalpha.com

Pasithea conducts 1-for-20 reverse stock split, gets FDA okay for study

January 2, 2024 | finance.yahoo.com

Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients

January 1, 2024 | benzinga.com

Pasithea Therapeutics Stock (NASDAQ:KTTA) Dividends: History, Yield and Dates

April 17, 2024 | InvestorPlace (Ad)

Forget Nvidia, buy this A.I. Stock Now

December 28, 2023 | finance.yahoo.com

Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023

December 19, 2023 | finance.yahoo.com

Pasithea Therapeutics Announces Results from 2023 Annual Meeting

December 13, 2023 | msn.com

Why Is Pasithea Therapeutics (KTTA) Stock Down 12% Today?

December 11, 2023 | msn.com

Neurology Focused Pasithea Therapeutics Stock Soars Over 150% Today - Here's Why

December 11, 2023 | markets.businessinsider.com

Pasithea Announces Positive In Vivo Preclinical Data For PAS-004

December 11, 2023 | msn.com

Pasithea stock soars as high as 190% on preclinical data

December 11, 2023 | investorplace.com

Why Is Pasithea Therapeutics (KTTA) Stock Up 105% Today?

December 11, 2023 | finance.yahoo.com

Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models

November 29, 2023 | finance.yahoo.com

Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders

November 29, 2023 | msn.com

Pasithea stock jumps 12% on update for anti-tumor drug PAS-004

November 29, 2023 | markets.businessinsider.com

Pasithea Announces Receipt Of FDA Response Of Pre-IND Meeting For PAS-004 Clinical Development

November 29, 2023 | finance.yahoo.com

Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development

November 9, 2023 | finance.yahoo.com

Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS

September 14, 2023 | finance.yahoo.com

Pasithea Therapeutics Corp. Announces Final Results of Tender Offer

September 7, 2023 | finance.yahoo.com

Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference

August 1, 2023 | finance.yahoo.com

Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved survival and motor function

July 20, 2023 | benzinga.com

What's Happening With Pasithea Therapeutics Stock Today?

July 20, 2023 | finance.yahoo.com

Pasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in Cash

See More Headlines

Receive KTTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pasithea Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/17/2024
Next Earnings (Estimated): 6/27/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:KTTA
CUSIP: N/A
CIK: 1841330
Web: www.pasithea.com
Phone: 702-514-4174
Fax: N/A
Employees: 15
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-15,960,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -49.04%
Return on Assets: -45.29%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.34
Quick Ratio: 6.34

Sales & Book Value

Annual Sales: $20,000.00
Price / Sales: 371.80
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $22.46 per share
Price / Book: 0.32

Miscellaneous

Outstanding Shares: 1,040,000
Free Float: 895,000
Market Cap: $7.44 million
Optionable: Not Optionable
Beta: 0.88

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Dr. Lawrence Steinman BA (Age 76)
M.D., Ph.D., Co-Founder, MD & Executive Chairman
Comp: $250k
Dr. Tiago Reis Marques M.D. (Age 47)
Ph.D., CEO & Director
Comp: $539.25k
Mr. Daniel H. Schneiderman (Age 46)
Chief Financial Officer
Comp: $327.91k
Dr. Yassine Bendiabdallah Ph.D. (Age 40)
COO & Head of UK Clinics
Dr. Graeme Currie Ph.D.
Chief Development Officer

Key Competitors

View All Competitors

Insiders

Lawrence Steinman
Bought 1,500 shares on 6/2/2023
Total: $12,900.00 ($8.60/share)

View All Insider Transactions

KTTA Stock Analysis - Frequently Asked Questions

How have KTTA shares performed in 2024?: Pasithea Therapeutics' stock was trading at $7.40 at the start of the year. Since then, KTTA stock has decreased by 3.4% and is now trading at $7.15.
View the best growth stocks for 2024 here.
When is Pasithea Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, June 27th 2024.
View our KTTA earnings forecast.
When did Pasithea Therapeutics' stock split?: Pasithea Therapeutics shares reverse split on Tuesday, January 2nd 2024. The 1-20 reverse split was announced on Tuesday, January 2nd 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

When did Pasithea Therapeutics IPO?: Pasithea Therapeutics (KTTA) raised $17 million in an IPO on Wednesday, September 15th 2021. The company issued 2,898,551 shares at $5.00-$7.00 per share.
How do I buy shares of Pasithea Therapeutics?: Shares of KTTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KTTA) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Pasithea Therapeutics (KTTA) Stock Price, News & Analysis

About Pasithea Therapeutics Stock (NASDAQ:KTTA)

KTTA Stock Price History

KTTA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

KTTA Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info